-19.4%
PCG vs MRNA
+159.5%
-179.0%
-43.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.7% | +1.3% | +0.4% | +1.7% |
| 7D | +7.5% | -13.8% | +21.3% | +7.6% |
| 30D | +5.8% | -17.7% | +23.4% | +5.9% |
| 3M | -20.7% | +14.3% | -35.0% | -20.9% |
| 6M | -14.5% | +336.0% | -350.4% | -17.7% |
| YTD | -12.4% | +575.9% | -588.3% | -18.1% |
| 1Y | -10.2% | +724.4% | -734.5% | -17.1% |
| All | -19.4% | +159.5% | -179.0% | -24.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling